World Journal of Pharmaceutical Science and Research

www.wjpsronline.com

Review Article

ISSN: 2583-6579
SJIF Impact Factor: 6.916
Year - 2026
Volume: 5; Issue: 7
Page: 620-636

GUT MICROBIOTA–DRUG INTERACTIONS: IMPACT ON DRUG METABOLISM, ABSORPTION, AND THERAPEUTIC OUTCOMES

Ajay Kumar S. N.[1], Gagana Shree D. S.[2], Madhurya N. G.[3], Reshma Banu S.*[4], Dr. E. Gopinath[5]

[1]Assistant Professor, Department of Pharmaceutics, Shantha College of Pharmacy, Peresandra, Chikkaballapur, Karnataka-562104

[2]Student, Shantha College of Pharmacy, Peresandra, Chikkaballapur, Karnataka-562104.

[3]Student, Shantha College of Pharmacy, Peresandra, Chikkaballapur, Karnataka-562104.

[4]Assistant Professor, Department of Pharmaceutics, Shantha College of Pharmacy, Peresandra, Chikkaballapur, Karnataka -562104.

[5]Principal, Department of Pharmaceutics, Shantha College of Pharmacy, Peresandra, Chikkaballapur, Karnataka-562104.

Article Received: 28 May 2026 | | Article Revised: 18 June 2026 | | Article Accepted: 09 July 2026

***Corresponding Author: Reshma Banu S.**
Assistant Professor, Department of Pharmaceutics, Shantha College of Pharmacy, Peresandra, Chikkaballapur, Karnataka-562104
DOI: https://doi.org/10.5281/zenodo.21371642

How to cite this Article: Ajay Kumar S. N., Gagana Shree D. S., Madhurya N. G., Reshma Banu S., Dr. E. Gopinath (2026) GUT MICROBIOTA–DRUG INTERACTIONS: IMPACT ON DRUG METABOLISM, ABSORPTION, AND THERAPEUTIC OUTCOMES. World Journal of Pharmaceutical Science and Research, 5(7), 620-636.

ABSTRACT

The gut microbiota plays a vital role in influencing drug absorption, metabolism, efficacy, and toxicity through direct microbial biotransformation and indirect modulation of host physiological processes. Variations in microbial composition contribute to differences in individual drug responses, affecting therapeutic outcomes and adverse effects. At the same time, several medications can alter gut microbial diversity, creating a dynamic bidirectional interaction between drugs and the microbiome. Recent advances highlight the potential of microbiome-based approaches to improve personalized medicine, optimize drug therapy, and predict treatment response. This review summarizes the key mechanisms underlying gut microbiota–drug interactions, discusses clinically relevant examples, and explores future perspectives for integrating microbiome profiling into pharmacological research and precision therapeutics.[1,2,3,5,6,12]

KEYWORDS: Gut microbiota; Drug metabolism; Drug absorption; Microbiome; Personalized medicine.

1. INTRODUCTION

The human body is inhabited by a vast and diverse community of microorganisms, including bacteria, fungi, viruses, and archaea, collectively known as the human microbiota. Among these microbial communities, the gut microbiota is the largest and most complex, containing over 100 trillion microorganisms and millions of genes. These microbes reside primarily in the large intestine and have co-evolved with humans, forming a mutually beneficial relationship that is essential for maintaining health. Traditionally, the gut microbiota was recognized for its role in digestion and nutrient absorption. However, recent advances in microbiome research have revealed that it functions as a dynamic metabolic organ capable of influencing numerous physiological processes, including immune regulation, hormone production, brain function, and, importantly, drug metabolism and absorption.[1,2,3,5,10,11]

The sequential metabolic checkpoints a drug encounters following oral administration. After absorption across the intestinal epithelium, the drug undergoes hepatic first-pass metabolism before a fraction is excreted via bile back into the gut lumen, where it is further metabolized by gut microbiota.[3,6,8,9]

This microbial exposure, increasingly studied under the field of pharmacomicrobiomics, can generate metabolic by-products that contribute to increased toxicity or alter the local gut metabolome.[4,8,12,20]

This integrated view reinforces the central argument of this section: gut microbiota are not a passive bystander in drug processing but an active determinant of drug efficacy, toxicity, and inter-individual variability in treatment response.[2,5,9,12,20]



Figure 1: Drug- Microbiota pharmacokinetic pathway.

The gut microbiota is composed of thousands of microbial species, with the dominant bacterial phyla being Firmicutes, Bacteroidetes, Actinobacteria, and Proteobacteria. The composition of these microbial communities varies among individuals and is influenced by factors such as age, genetics, diet, lifestyle, environmental exposure, geographical location, disease conditions, and the use of medications, particularly antibiotics. A healthy and diverse gut microbiota is essential for maintaining intestinal homeostasis, while disturbances in microbial composition, known as dysbiosis, have been associated with various disorders including inflammatory bowel disease, obesity, diabetes, cardiovascular diseases, neurological disorders, and several types of cancer.[2,5,11,19]

In recent years, growing scientific evidence has highlighted the significant role of the gut microbiota in determining the fate of orally administered drugs. Once a drug enters the gastrointestinal tract, it encounters trillions of microorganisms

before it reaches systemic circulation. These microbes possess a wide variety of enzymes that can chemically modify drug molecules through reactions such as reduction, hydrolysis, deconjugation, acetylation, and decarboxylation. Such microbial transformations may activate inactive drugs, inactivate active drugs, generate toxic metabolites, or alter the pharmacological activity of medications. Consequently, the gut microbiota has become an important determinant of drug efficacy, safety, and therapeutic outcomes.[6,8,9,13,24]

2. Gut Microbiota's Effect on Drug Absorption

Gut microbiota affects oral drug absorption through several routes beyond direct metabolism.[10,25,26,30]

- *Chemical modification in the gut lumen* — e.g., microbial nitroreductases convert berberine into dihydroberberine, which absorbs ~5x more efficiently.[6,8,25]
- *Regulation of drug transporters* — gut metabolites can down-regulate efflux pumps like MDR1/P-glycoprotein, increasing absorption; dysbiosis can do the opposite, sharply reducing it.[10,11,25,30]
- *Intestinal permeability* — microbiota shapes tight-junction integrity; germ-free animals show higher gut permeability than colonized ones, affecting how drugs cross the barrier.[2,10,11,25]
- *Enterohepatic recirculation* — bacterial β-glucuronidase reactivates liver-deactivated drugs, sending them back for reabsorption and extending exposure.[6,8,9,13,20



Figure 2: Drug-Microbiota pharmacokinetic pathway.

Overall, the impact depends on the drug's properties — highly soluble/permeable drugs (e.g., acetaminophen) are barely affected, while drugs needing active transport (e.g., metformin) or paracellular absorption are far more sensitive to microbiota changes.[10,25,26,30]

Drug absorption is another crucial process influenced by the gut microbiota. The intestinal epithelium serves as the primary site for the absorption of orally administered medications. Gut microorganisms help maintain the integrity of the intestinal barrier by regulating mucus production, strengthening tight junction proteins, and producing beneficial metabolites such as short-chain fatty acids (SCFAs). These metabolites improve intestinal health and influence the permeability of the gut wall, thereby affecting the amount of drug that enters the bloodstream. Furthermore, gut microbes can regulate the expression and activity of drug transport proteins such as P-glycoprotein (P-GP) and influence host metabolic enzymes like the cytochrome P450 (CYP450) family, creating a complex interaction between microbial metabolism and host physiology.[10,11,25,30]

The relationship between drugs and the gut microbiota is bidirectional. While gut microorganisms can modify the metabolism and absorption of drugs, many medications can also alter the composition and function of the gut microbiota. Antibiotics are the most obvious example, as they can significantly reduce microbial diversity and disrupt normal microbial balance -steroidal anti-inflammatory drugs (NSAIDs), metformin, statins, antidepressants, anti-cancer drugs have also been shown to influence gut microbial communities. These drug-induced alterations may affect future drug responses and contribute to adverse effects or treatment failure.[5,12,18,27]

3. Role of Gut Microbiota in Drug Metabolism

The gut microbiota plays a significant role in drug metabolism by modifying the chemical structure of many orally administered drugs before they are absorbed or after they are excreted into the intestine. These microbial transformations can alter a drug's pharmacokinetics and pharmacodynamics, affecting its bioavailability, efficacy, and toxicity. Unlike hepatic metabolism, which is carried out by host enzymes, gut microbial metabolism is mediated by a wide range of bacterial enzymes. The extent of these interactions varies among individuals because the composition of the gut microbiota differs from person to person, contributing to variability in drug response.[2,6,8,9,13,28]

Microbial enzymes also contribute to drug toxicity. Bacterial Beta-glucuronidase enzymes reactivate inactivate drug metabolites excreted into the intestine through bile. In the case of the anticancer drug irinotecan, bacterial beta glucuronidase converts its inactive glucuronide metabolite [SN-38G] back to the active toxic metabolite [SN-38], leading to severe diarrhea and intestinal damage.[6,8,9,13,20]

The gut microbiota further influences drug metabolism by regulating the expression of host metabolism by regulating the expression of host metabolic enzymes and transporters such as cytochrome P450 enzymes and P-glycoprotein. Microbial metabolites, particularly short chain fatty acids (SCFAs) like butyrate, acetate, and propionate, can modulate liver enzyme activity and alter drug metabolism indirectly. This bidirectional interaction demonstrates that gut microbes not only metabolize drugs directly but also affect the hosts metabolic capacity.[10,11,25,28,30]



Figure 3: Gut Microbiota in drug Metabolism.

3.1 Direct Microbial Metabolism of Drugs

Gut microorganisms can directly metabolize drugs through reduction, hydrolysis, Dehydroxylation, deacetylation, and demethylation reactions. These transformations may activate prodrugs, inactivate active drugs, or produce metabolites with altered therapeutic or toxic effects.[6,8,9,13,15,28]

Examples include

- *Sulfasalazine:* Bacterial Azo reductase enzymes cleave the azo bond of sulfasalazine to produce the active compounds 5-aminosalicylic acid (5-ASA) and Sulfa pyridine, enabling treatment of inflammatory bowel disease.[8,9,13]
- *Digoxin:* Certain strains of *Eggerthella lenta* can inactivate digoxin by reducing it to inactive metabolites, decreasing its therapeutic efficacy.[6,9,13,20]
- *Irinotecan*: After hepatic metabolism, bacterial β-glucuronidase enzymes reactivate irinotecan metabolites in the intestine, contributing to severe gastrointestinal toxicity such as diarrhea.[6,8,9,20]
- *Levodopa*: Intestinal bacteria can metabolize levodopa before it reaches the brain, reducing the amount of drug available for the treatment of Parkinson's disease.[6,13,24]

These examples demonstrate that gut microorganisms can significantly influence the clinical response to many medications.[6,8,9,13,20,24]

3.2 Enzymes Involved in Microbial Drug Metabolism

Gut bacteria produce a diverse range of enzymes that participate in drug biotransformation. Important microbial enzymes include.[6,8,9,13,28]

- *Azo reductases*: Break azo bonds in drugs such as sulfasalazine, releasing active therapeutic compounds.
- *β-Glucuronidases*: Remove glucuronic acid from drug metabolites, causing drug reactivation and sometimes increasing toxicity.
- *Nitroreductases:* Reduce nitro-containing drugs to active or inactive metabolites.
- *Hydrolases:* Hydrolyze ester and amide bonds, altering drug structure and activity.
- *De hydroxylases*: Remove hydroxyl groups from certain drug molecules, affecting their biological activity.
- *Demethylases:* Remove methyl groups, leading to changes in drug potency and metabolism.

The activity of these enzymes depends on the composition and metabolic capacity of the gut microbiota. Variations in microbial enzyme expression among individuals contribute to differences in drug efficacy, adverse drug reactions, and personalized responses to pharmacotherapy. Advances in metagenomic and metabolomic profiling are increasingly enabling researchers to map these enzyme activities to specific bacterial taxa, offering a clearer picture of how individual microbiome compositions influence drug outcomes. This growing understanding of microbial enzymatic diversity holds promise for developing predictive biomarkers that could guide personalized dosing strategies and minimize adverse drug reactions in clinical practice.[6,12,13,26,30]

4. Gut Microbiota and Therapeutic Outcomes

Beyond metabolism and absorption, gut microbiota composition directly shapes how well a drug works — and this is most clearly demonstrated with immune checkpoint inhibitors (ICIs) in cancer immunotherapy.[20,21,26]

- *Direct link to response rates*: - Specific bacterial genera linked to better outcomes: *Akkermansia muciniphila*, *Faecalibacterium*, and certain *Ruminococcaceae* are associated with improved response to anti-PD-1 therapy (not just CTLA-4). High microbiome diversity generally correlates with better response and fewer immune-related adverse events.[20,21,26]

- *Clinical translation*: - Preclinical work showed antibiotic-treated or germ-free tumor-bearing mice respond poorly to CTLA-4 blockade, and supplementing specific *Bacteroides* species restores efficacy by activating anti-tumor immune cells.
- Human studies since 2018 have confirmed a strong link between gut microbiota composition and ICI outcomes Because of this link, gut microbiota is now studied as both a predictive biomarker (machine-learning models using pre-treatment microbiome data to forecast response) and a modifiable target — fecal microbiota transplantation has shown early success improving ICI response by correcting unfavorable microbiome states.[20,21,22]
- *Beyond cancer immunotherapy, the same principle*: -microbiota shaping therapeutic outcome, not just pharmacokinetics — applies broadly: it can determine whether a prodrug gets activated, whether toxic byproducts form, and how consistently a drug performs across patients.[5,12,20,26]

5. Drug-microbiota interaction effects

Table 1: Drug microbiota interaction effects.

Drug	Bacteria / Enzyme	Effect
Sulfasalazine	Azo reductase	Activation-5-ASA
Digoxin	Eggerthella Lenta	Inactivation
Irinotecan	β-Glucuronidase	Reactivation-Toxicity
Levodopa	Gut Bacteria	Reduced bioavailability
Gemcitabine	Cytidine deaminase	Inactivation

Gut bacteria interact with structurally diverse drugs through distinct enzymes, producing outcomes ranging from activation to inactivation and toxic reactivation. This variability reflects differences in individual microbiome composition and helps explain inconsistent drug efficacy and toxicity across patients, underscoring the clinical importance of characterizing these interactions for personalized pharmacotherapy.[6,8,9,13,20]

The outcome of these interactions varies among individuals because the composition and metabolic activity of the gut microbiota differ from person to person. Consequently, the same drug can produce different therapeutic responses or adverse effects in different patients. Understanding these microbial pathways is increasingly important in pharmacology, as they provide insights into interindividual variability in drug response and support the development of personalized medicine. Overall, the drug–microbiota interaction pathway highlights the crucial role of gut microorganisms in determining the safety, effectiveness, and clinical outcome of many therapeutic agents.[1,2,5,12,20,26]



Figure 4: Enterohepatic circulation pathway of orally administered drug.

First-pass effect note at the Liver step — some drug gets metabolized before ever reaching systemic circulation, reducing the amount that's actually active. Target Tissue/Organ node off systemic circulation — shows where the drug actually produces its effect, not just where it travels. Protein binding note in the blood step — only the "free" (unbound) drug is active and available to tissues or filtration.[6,8,20,24]

6. Animal Studies on Gut Microbiota–Drug Interactions: Animals and Drugs Tested.

6.1Background and Rationale

Animal models provide the foundational, mechanistic evidence for gut microbiota–drug interactions before findings are translated into human clinical research.

Human microbiome studies are confounded by variability in diet, genetics, and environment, making controlled animal models essential for establishing causality.[13,15,20,21]

6.2 Types of Animal Models Used

Germ-free (GF) mice — completely lack gut microbiota, used as a baseline comparison
Gnotobiotic mice — colonized with defined, known bacterial strains.
Antibiotic-treated conventional mice — microbiota depleted or altered pharmacologically

Fecal microbiota transplantation (FMT) models — used to transfer specific microbial phenotypes between animals.[13,15,21,22]

6.3 Significance of Animal Models in This Field

Allow direct comparison of drug pharmacokinetics/pharmacodynamics with and without gut microbiota present
Isolate the microbiome's specific contribution to drug absorption, metabolism, and toxicity.

Enable identification of causal relationships, not just correlations.[6,13,15,20]

6.4 Key Findings Established Through Animal Studies

Specific bacterial species/enzymes responsible for individual drug interactions (e.g. *Eggerthella lenta* inactivating digoxin, bacterial β-glucuronidase reactivating irinotecan)

Dose-toxicity relationships that would be unethical to test directly in humans.
Histopathological changes in gut and liver tissue following microbial drug metabolism
Long-term consequences of microbiome depletion (via antibiotics) on drug efficacy

Confirmation via FMT that transferring a microbial community also transfers its drug-metabolizing phenotype.[6,9,13,20,21]



Figure 5: Animal Studies of Gut Microbiota Interactions.

Animal studies collectively demonstrate that gut microbiota plays a crucial role in drug metabolism, activation, efficacy, and toxicity. Microbiota can bioactivate prodrugs inactivate drugs (digoxin), modulate immune-mediated drug efficacy (cyclophosphamide, checkpoint inhibitors), and alter systemic drug toxicity (paracetamol). personalized pharmacotherapy and Drug safety.[6,13,20,21]

7. Human/Clinical Studies on Gut Microbiota-Drug Interactions

Clinical data confirm that microbiota-drug interactions seen in animals also occur in humans, affecting drug efficacy and toxicity.[2,20,24,26]

- *Digoxin*: Patients with high *Eggerthella lenta* levels show reduced digoxin bioavailability, requiring dose adjustment.[6,9,13,20]
- *Irinotecan:* Gut bacterial β-glucuronidase reactivates the drug's toxic metabolite, causing diarrhea/enteropathy in cancer patients; antibiotics reduce this toxicity.[6,8,9,20]
- *Immune checkpoint inhibitors*: Gut microbiome composition correlates with response and colitis risk in melanoma, NSCLC, and renal cell carcinoma patients; fecal transplants from responders improve outcomes, while antibiotic use worsens them.[20,21,26
- *Sulfasalazine*: Bacterial azoreductase activity is essential for converting it into active anti-inflammatory metabolites in IBD patients.[8,9,13]



Figure 6: Human/ Clinical Studies Gut Microbiota

Human studies validate animal findings but show more variability due to individual microbiome differences, diet, and antibiotic history — supporting the need for microbiome-based biomarkers in personalized therapy.[1,12,20,26]

8. Effect of Drugs on Gut Microbiota Composition

Just as microbiota affects drugs, many drugs alter gut microbiota composition and diversity — a bidirectional relationship.[5,12,18,27]

- *Antibiotics*: Cause significant dysbiosis, reduced microbial diversity, and loss of beneficial species; effects can persist for months and impair drug metabolism capacity.[20,21,27]
- *Chemotherapy* (e.g., cyclophosphamide, irinotecan): Disrupts gut barrier and microbial balance, contributing to GI toxicity and altered immune response.[20,21,27]
- *Proton pump inhibitors (PPIs):* Reduce gastric acid, allowing oral/upper GI bacteria to colonize the gut, altering microbial composition.[5,18,27]
- *Metformin:* Alters gut microbiota (increases *Akkermansia muciniphila* and short-chain fatty acid producers), which partly contributes to its glucose-lowering effect.[20,26,27]
- *NSAIDs*: Associated with reduced microbial diversity and increased intestinal permeability, worsening enteropathy risk. Drug-induced dysbiosis can create a feedback loop — altering microbiota not only affects the drug's own metabolism but also impacts the efficacy/toxicity of subsequent therapies.[5,18,27]

9. Methods and Tools Used to Study Microbiota–Drug Interactions

- *Germ-free / gnotobiotic animal models* — microbe-free animals selectively colonized with defined organisms or donor microbiota to isolate the microbiome's role in drug response; antibiotic-depleted "pseudo-germ-free" mice used as a lower-cost alternative.[13,15,21,22]

- *Fecal microbiota transplantation (FMT) / humanized mouse models* — human donor stool transferred into germ-free or antibiotic-treated rodents to study individualized, donor-specific drug–microbiome responses (e.g., linked to metformin's therapeutic effect in type 2 diabetes).[20,21,22]
- *In vitro gut simulators (e.g., SHIME®)* — multi-compartment bioreactors replicating stomach-to-colon conditions, used as a "clinical trial in vitro" to test drug/antibiotic combinations and microbiota recovery.[22,23]
- *Culturomics* — large-scale culturing of gut bacterial strains to directly test drug-metabolizing capacity (e.g., probiotic panels metabolizing a majority of tested drugs).[13,15,23]
- *High-throughput culture/metaproteomic screens (e.g., Rapid AIM)* — parallel testing of many compounds against individual microbiome samples to capture person-to-person variability.[13,15,23]
- *Metagenomics* — shotgun sequencing to profile microbial taxa and functional genes (e.g., drug-metabolizing enzyme genes). (6,12,13,23)
- *Metabolomics*— LC-MS/MS-based identification of microbial drug metabolites.[6,12,23]
- *Metaproteomes* — profiling of actively expressed microbial proteins for functional insight beyond gene presence.[13,23]
- *Computational/database tools (MDAD, MASI, MagMD)* — curated databases and prediction pipelines for known or likely microbe–drug interactions, enabling hypothesis generation before lab testing.[12,23]

A range of in vivo, in vitro, and computational tools are used to study microbiota–drug interactions, moving from whole-animal physiology down to molecular mechanisms. Germ-free and humanized mouse models allow drugs to be tested in a living host with a defined or donor-derived microbiota, and have practical applications in linking specific microbial communities to drug outcomes (e.g., metformin's efficacy in type 2 diabetes), though they remain costly, technically demanding, and imperfect proxies for the normal human gut due to immune and developmental differences in germ-free animals and variable engraftment in FMT models.[13,15,22]

In vitro gut simulators such as SHIME® offer a faster, more controlled alternative — effectively a "clinical trial in vitro" — useful for screening long-term or repeated drug dosing and antibiotic combinations without the cost and ethical burden of animal work, though they lack host immune and absorptive components and so cannot fully capture systemic drug effects.[22,23]

Culturomics and high-throughput screening platforms (e.g., Rapid AIM) allow direct, scalable testing of how individual strains or whole microbiome samples metabolize drug panels, preserving person-to-person variability that is valuable for personalized-medicine research, but many gut taxa remain unculturable and monoculture results don't always reflect community-level behavior.[13,15,22,23]

Finally, omics and computational approaches — metagenomics, metabolomics, meta proteomics, and curated interaction databases (MDAD, MASI, MagMD) — identify which microbes, genes, and metabolites are involved and help predict likely drug–microbiome interactions before lab testing. These are powerful for hypothesis generation and mechanistic insight, but gene or protein presence doesn't guarantee functional activity, and computational predictions still require experimental validation.[6,12,13,15,23]

10. Factors Influencing Microbiota–Drug Interactions

- *10.1Diet:* - Diet is one of the most modifiable and influential factors: dietary compounds significantly reshape the gut microbiome — for example, plant sterol esters produce marked compositional changes, while oat beta-glucan causes more modest shifts, and some drugs like atorvastatin barely affect microbial communities at all. Since diet-driven microbial shifts can alter host physiology through microbial metabolism, gene regulation, and immune activation, they may in turn modulate drug pharmacokinetics or clinical outcomes.[5,25,26]
- *10.2Age:* - Microbial composition evolves across the lifespan, from infancy through old age, and these age-related shifts affect the enzymatic and metabolic capacity of the microbiome available to interact with drugs.[2,11]
- *10.3 Disease state:* - Underlying disease can both drive and be driven by microbiota alterations relevant to drug response — for instance, dysbiosis is implicated in the pathogenesis of conditions like irritable bowel syndrome, and in rheumatoid arthritis, gut microbiota composition has been linked to the treatment efficacy of disease-modifying anti-rheumatic drugs.[5,19,20]
- *10.4 Antibiotic history:* - Prior or ongoing antibiotic exposure is one of the most disruptive factors, reducing microbial diversity, altering metabolic activity, and favoring resistant strains; tetracyclines, for example, significantly and sometimes durably reduce Bifidobacterium abundance, with recovery taking weeks to months depending on individual resilience. Because antibiotic-induced dysbiosis changes the community available to metabolize subsequent drugs, antibiotic history itself becomes a variable in later drug response.[12,18]
- *10.5 Host genetics:* - Host genetic background shapes microbiota composition and interacts with environmental exposures to determine the makeup of the gut community; even genetic differences within the same microbial species can drive differential drug metabolism, complicating outcome prediction. Notably, one review found that genetic diversity alone explains only a limited proportion of individual variability in drug response, positioning the microbiota as a major additional axis beyond the human genome.[10,26,30]
- *10.6 Inter-individual and intra-individual variability:* - Beyond genetics, factors like mode of delivery at birth, feeding practices, health status, stress, and environmental exposures collectively shape each person's microbiota.

Unlike the human genome, the gut microbiota is described as remarkably adaptive and "cloud-like," fluctuating with spatial, seasonal, hormonal, and dietary changes — meaning drug-response-relevant microbiota can shift even within the same individual over time.[2,5,26]

These factors don't act in isolation — they converge to shape microbiota composition, which then drives person-to-person differences in drug metabolism, efficacy, and toxicity. This is a core reason gut microbiota is increasingly considered alongside host genetics in predicting individual drug response.

Importantly, genetic variation alone explains only a limited portion of individual differences in drug response — the microbiota is increasingly viewed as a second, largely environmentally-shaped layer that helps account for the rest.

Because it is more dynamic and modifiable than the human genome, this also means microbiota-related variability is not fixed: diet changes, probiotic use, or recovery time after antibiotics can shift a person's drug-response profile over the course of treatment, not just between different patients. This adaptability is part of why researchers see the microbiota as both a challenge for predicting drug response and a potential lever for improving it — for example, by timing drug administration around diet, or allowing microbiota recovery before starting a drug known to interact strongly with gut bacteria.[10,12,26,30]

Clinical Implications and Pharmacomicrobiomics

Pharmacomicrobiomics is the emerging field studying how variation in the gut microbiome affects drug pharmacokinetics and pharmacodynamics — and how, conversely, drugs reshape the microbiome. It is increasingly viewed alongside pharmacogenomics as a "second genome" contributing to individual drug response, since host genetics alone explains only part of the variability seen between patients.[4,12,20,26]

Clinically, this has a few concrete applications: predictive algorithms that combine microbiome and clinical data (e.g., vedoNet for IBD treatment response) are being developed to forecast individual drug efficacy; microbial signatures are being explored as biomarkers to flag patients at risk of toxicity or non-response before treatment starts; and researchers are increasingly proposing microbiome-informed personalized dosing, similar to how pharmacogenomic testing already guides dosing for some drugs. AI-based models are also being explored to identify these microbial biomarkers and integrate them with clinical data for treatment decisions, though regulatory frameworks for this kind of AI-driven, microbiome-guided prescribing are still evolving.[12,20,26]



Figure 7: Clinical Implications and Pharmacomicrobiomics.

Gut microbiota modulates oral drug absorption, activity, and toxicity in the GI tract, giving rise to four subfields: Pharmacomicrobiomics (microbiome effects on drug absorption/activity/toxicity), Pharmacoecology (microbiome changes from drug administration), Toxic microbiomics (microbiome variation affecting toxicity), and Pharma coinfection (pathogen effects on drug.[12,20,26]

The host and microbiome regulate each other's clocks, and drug metabolism sits downstream of both. Since gut bacteria help maintain the host's circadian rhythm, and host circadian genes in turn control liver and gut drug-metabolizing enzymes and gut-barrier permeability, a drug's fate depends on two intertwined clocks — the host's and the microbiome's — not either one alone.[4,12,30]

Drugs can, in turn, desynchronize the microbiome. Antibiotics and other drugs that disturb microbial composition don't just remove or add species — they can strip out the microbiome's rhythmic gene activity itself, which may feedback to

disrupt the host's own metabolic timing, creating a cycle where drug exposure and microbial/circadian disruption reinforce each other.[4,12,18,30]

11. Dynamic Relationship Shapes Therapeutic Outcomes

11.1 Chronotherapy implications

If microbial gene activity and gut-barrier permeability both cycles daily, then the same dose given at different times could plausibly produce different absorption, metabolism, or toxicity profiles in the same patient — suggesting drug timing itself may be an underexplored lever for improving efficacy or reducing side effects, not just dose size. (4,12,30)

11.2 Outcome variability *without composition change*

A patient's microbiome can look identical on a taxonomic snapshot yet behave differently hour to hour, meaning two "same microbiome" patients — or the same patient tested at different times — could show different treatment responses purely due to rhythm misalignment, not any real difference in who's present. (4,12,26,30)

11.3 Feedback loop in drug Response

A feedback loop that can compound treatment failure. If a drug disrupts microbial rhythmicity (not just composition), and that disruption feeds back to desynchronize the host's own metabolic clock, poor early response to a drug could progressively worsen the very system needed to metabolize it effectively — a compounding effect rather than a one-off pharmacokinetic issue.[4,12,18,30]

Shift workers, jet lag, and irregular routines as a hidden variable. Since lifestyle factors that disrupt circadian rhythm (irregular sleep, shift work, inconsistent meal timing) are known to desynchronize gut microbial rhythms, these everyday factors — rarely tracked in drug trials — could be a silent contributor to real-world therapeutic variability that's missed in controlled clinical studies.[4,12,30]

Reframes "personalized medicine" beyond a single microbiome snapshot. Most current pharmacomicrobiomic approaches (biomarker panels, one-time stool sampling) treat the microbiome as static. This dynamic view suggests true personalization may eventually need to account for when a person's microbiome is most functionally primed to metabolize a given drug — not just what microbes they carry.[12,20,26,30]

12. Future Directions

12.1 Precision/core probiotics

Rather than broad-spectrum FMT, future approaches aim to identify specific functional genes and metabolic pathways in the microbiome and select "core" probiotic strains targeted to those functions — offering more predictable, mechanism-based interventions than transplanting an entire donor community.[5,12,20]

12.2 Probiotics/prebiotics as treatment adjuncts

Growing evidence points to combining probiotics or symbiotic alongside conventional drug therapy — for example, gut microbiota composition has been shown to regulate the efficacy of sulfasalazine in inflammatory bowel disease, suggesting deliberate microbiome modulation could become a standard adjunct for optimizing specific drug responses rather than an afterthought.[2,20,21]

12.3 AI-based prediction models

Machine learning and deep learning are increasingly applied to microbiome data for tasks like taxonomic/functional profiling, predicting drug-microbe interactions, forecasting toxicity, and supporting drug repurposing. Translational and regulatory groundwork. Tools like organ-on-a-chip systems, organoids, and 3D cell culture are being proposed to bridge the preclinical-to-clinical gap for live biotherapeutic products, while falling sequencing costs are expected to make larger, more diverse microbiome datasets economically feasible — a prerequisite for training more generalizable AI models and building clearer regulatory pathways for microbiome-based drugs.[12,22,23]

13. CONCLUSION

The gut microbiota has emerged as a key determinant of drug response, significantly influencing the absorption, metabolism, efficacy, and toxicity of numerous therapeutic agents. Through direct microbial biotransformation and indirect modulation of host physiological processes, intestinal microorganisms can alter drug bioavailability, pharmacokinetics, and pharmacodynamics, ultimately affecting therapeutic outcomes. Conversely, many commonly prescribed medications, including antibiotics, proton pump inhibitors, metformin, and nonsteroidal anti-inflammatory drugs, can modify the composition and function of the gut microbiota, creating a dynamic bidirectional interaction between drugs and the microbial community.[6,10,12,20,26]

These microbiota–drug interactions help explain the considerable variability in drug response observed among individuals, even when genetic and environmental factors are similar. Understanding these interactions provides valuable insights into treatment failure, adverse drug reactions, and differences in therapeutic efficacy. Recent advances in microbiome research, including metagenomics, metabolomics, and microbiome-targeted interventions such as probiotics, prebiotics, and fecal microbiota transplantation, offer promising opportunities to optimize drug therapy and improve clinical outcomes. Future integration of microbiome profiling into routine clinical practice may enable more precise, personalized, and effective pharmacotherapy. Continued interdisciplinary research will be essential to translate these discoveries into safe, evidence-based therapeutic strategies that maximize drug efficacy while minimizing toxicity.[6,10,12,20,26]

REFERENCES

1. Bäckhed F, Ley RE, Sonnenburg JL, Peterson DA, Gordon JI. Host-Bacterial Mutualism in the Human Intestine. Science, 2005; 307(5717): 1915–1920. https://doi.org/10.1126/science.1104816
2. Marchesi JR, Ravel J. The vocabulary of microbiome research: a proposal. Microbiome, 2015; 3: 31. https://doi.org/10.1186/s40168-015-0094-5
3. Scarpellini E, Ianiro G, Attili F, et al. The human gut microbiota and virome: Potential therapeutic implications. Dig Liver Dis, 2015; 47(12): 1007–1012. https://doi.org/10.1016/j.dld.2015.07.008
4. Voigt RM, Forsyth CB, Green SJ, et al. Circadian Disorganization Alters Intestinal Microbiota. PLoS One, 2014; 9(5): e97500. https://doi.org/10.1371/journal.pone.0097500
5. Sousa T, Paterson R, Moore V, et al. The gastrointestinal microbiota as a site for the biotransformation of drugs. Int J Pharm, 2008; 363(1–2): 1–25. https://doi.org/10.1016/j.ijpharm.2008.07.009
6. El Aidy S, van den Bogert B, Kleerebezem M. The small intestine microbiota, nutritional modulation and relevance for health. Curr Opin Biotechnol, 2015; 32: 14–20. https://doi.org/10.1016/j.copbio.2014.09.005

7. Mani S, Boelsterli UA, Redinbo MR. Understanding and Modulating Mammalian–Microbial Communication for Improved Human Health. Annu Rev Pharmacol Toxicol, 2014; 54: 559–580. https://doi.org/10.1146/annurev-pharmtox-011613-135559
8. Gingell R, Bridges JW, Williams RT. The Role of the Gut Flora in the Metabolism of Prontosil and Neoprontosil. Xenobiotica, 1971; 1(2): 143–156. https://doi.org/10.3109/00498257109038763
9. Prudhviraj G, Vaidya Y, Singh SK, et al. Effect of co-administration of probiotics with polysaccharide-based colon targeted delivery systems. Eur J Pharm Biopharm, 2015; 97: 164–172. https://doi.org/10.1016/j.ejpb.2015.08.003
10. Peppercorn MA, Goldman P. The role of intestinal bacteria in the metabolism of salicylazosulfapyridine. J Pharmacol Exp Ther, 1972; 181(3): 555–562.
11. Mikov M, Lee HJ, Fawcett JP. The influence of probiotic treatment on sulfasalazine metabolism in rat gut contents. Asian Journal of Pharmacokinetics and Pharmacodynamics, 2006; 6: 337–342. Link: https://www.researchgate.net/publication/285844729_The_influence_of_probiotic_treatment_on_sulfasalazine_metabolism_in_rat_gut_contents
12. Yoo DH, Kim IS, Van Le TK, Jung IH, Yoo HH, Kim DH. Gut microbiota-mediated drug interactions between lovastatin and antibiotics. Drug Metabolism and Disposition, 2014; 42(9): 1508–1513. https://doi.org/10.1124/dmd.114.058057
13. Matuskova Z, Anzenbacherova E, Vecera R, et al. Administration of a probiotic can change drug pharmacokinetics: Effect of Escherichia coli Nissle 1917 on amiodarone absorption in rats. PLOS ONE, 2014; 9: e87150. https://doi.org/10.1371/journal.pone.0087150
14. Wallace BD, Wang H, Lane KT, et al. Alleviating Cancer Drug Toxicity by Inhibiting a Bacterial Enzyme. Science, 2010; 330(6005): 831–835. https://doi.org/10.1126/science.1191175
15. Kehrer DFS, Sparreboom A, Verweij J, et al. Modulation of Irinotecan-Induced Diarrhea by Cotreatment with Neomycin in Cancer Patients. Clinical Cancer Research, 2001; 7(5): 1136–1141. https://aacrjournals.org/clincancerres/article/7/5/1136/288842
16. Saitta KS, Zhang C, Lee KK, et al. Bacterial β-glucuronidase inhibition protects mice against enteropathy induced by indomethacin, ketoprofen or diclofenac. Xenobiotica, 2014; 44(1): 28–35. https://doi.org/10.3109/00498254.2013.824418
17. Liang X, Bittinger K, Li X, et al. Bidirectional interactions between indomethacin and the murine intestinal microbiota. eLife, 2015; 4: e08973. https://doi.org/10.7554/eLife.08973
18. Saha JR, Butler VP Jr, Neu HC, Lindenbaum J. Digoxin-inactivating bacteria: Identification in human gut flora. Science, 1983; 220(4594): 325–327. https://doi.org/10.1126/science.6836275
19. Haiser HJ, Gootenberg DB, Chatman K, et al. Predicting and Manipulating Cardiac Drug Inactivation by the Human Gut Bacterium Eggerthella lenta. Science, 2013; 341(6143): 295–298. https://doi.org/10.1126/science.1235872
20. Lindenbaum J, Rund DG, Butler VP Jr, Tse-Eng D, Saha JR. Inactivation of Digoxin by the Gut Flora: Reversal by Antibiotic Therapy. New England Journal of Medicine, 1981; 305(14): 789–794. https://doi.org/10.1056/NEJM198110013051403
21. Cole CB, Fuller R, Mallet AK, Rowland IR. The influence of the host on expression of intestinal microbial enzyme activities involved in metabolism of foreign compounds. J Appl Bacteriol, 1985. DOI: https://doi.org/10.1111/j.1365-2672.1985.tb03359.x

22. Akao T, Kawabata K, Yanagisawa E, et al. Predominant flavone glucuronides are hydrolyzed in the rat gastrointestinal tract. J Pharm Pharmacol, 2000. DOI: https://doi.org/10.1211/0022357001777621
23. Sato Y, Atrash K, Plichta DR, et al. Near-complete human gut microbial genomes encoded in thousands of species. Nature, 2024. DOI: https://doi.org/10.1038/s41586-024-03832-5
24. Haden H, Sallam LA, Devendran S, et al. Developmental and regional metabolism of oxo-bile acids. Appl Environ Microbiol, 2018. DOI: https://doi.org/10.1128/AEM.00235-18
25. Dodd D, Cann I. Tutorial: microbiome studies in drug metabolism. Clin Transl Sci., 2022. DOI: https://doi.org/10.1111/cts.13416
26. Sousa T, Yadav V, Zann V, et al. On the colonic bacterial metabolism of azo compounds. J Pharm Sci, 2014. DOI: https://doi.org/10.1002/jps.24103
27. Maini Rekdal V, Bess EN, Bisanz JE, et al. Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism. Science, 2019. DOI: https://doi.org/10.1126/science.aau6323
28. Zimmermann M, Zimmermann-Kogadeeva M, Wegmann R, Goodman AL. Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature, 2019. DOI: https://doi.org/10.1038/s41586-019-1291-3
29. Li D, Chen Y, Wan M, Mei F, Wang F, Gu P, et al. Oral magnesium prevents acetaminophen-induced acute liver injury by modulating microbial metabolism. Cell Host & Microbe, 2023. DOI: https://doi.org/10.1016/j.chom.2023.11.006
30. Javan B, Lopez JG, Chankhamon P, Lee YJ, Hull R, Wu Q, et al. Personalized mapping of drug metabolism by the human gut microbiome. Cell, 2020. DOI: https://doi.org/10.1016/j.cell.2020.05.001
31. van de Steeg E, Schuren FHJ, Obach RS, van de Water B, et al. An ex vivo fermentation screening platform to study drug metabolism by human gut microbiota. Drug Metabolism and Disposition, 2018. DOI: https://doi.org/10.1124/dmd.118.081286
32. Viglioli M, Rizzo SM, Alessandri G, et al. Investigating drug–gut microbiota interactions using an hydrolytic metabolism model. International Journal of Pharmaceutics, 2024. DOI: https://doi.org/10.1016/j.ijpharm.2024.124663
33. Poeker SA, Geirnaert A, Berchtold L, et al. Understanding the prebiotic potential of dietary fibers using an in vitro continuous adult fermentation model. Scientific Reports, 2018. DOI: https://doi.org/10.1038/s41598-018-22438-y
34. Ladar SE, Schols HA, Nauta A, et al. High-throughput analysis of the impact of antibiotics on the human intestinal microbiota composition. Journal of Microbiological Methods, 2013. DOI: https://doi.org/10.1016/j.mimet.2012.12.011
35. Gagniere J, Raisch J, Veziant J, et al. Gut microbiota imbalance and colorectal cancer. World Journal of Gastroenterology, 2016. DOI: https://doi.org/10.3748/wjg.v22.i21.501
36. Zheng DW, Dong X, Zhang QL, et al. Controllable generation of artificial extracellular matrix for altering mass transport and improving cancer therapies. Nature Communications, 2020. DOI: https://doi.org/10.1038/s41467-020-18493-7
37. Rodenhizer D, Gaude E, Cojocari D, et al. A three-dimensional engineered tumour for hypoxia analysis of cell metabolism and phenotype. Nature Materials, 2016. DOI: https://doi.org/10.1038/nmat4482
38. Grigoriev P, Paulsen SJ, Corbett DC, et al. Functional vascular networks and functional intravascular topologies within biocompatible hydrogels. Science, 2019. DOI: https://doi.org/10.1126/science.aav9750

39. McCoubrey LE, Shen C, Mwasambu S, et al. Characteristic fingerprinting of gut microbiota's inactivation of trifluridine. European Journal of Pharmaceutical Sciences, 2024. DOI: https://doi.org/10.1016/j.ejps.2024.106922
40. Alam Y, Hakopian S, Ortiz de Ora L, et al. Variation in human gut microbiota impacts tamoxifen pharmacokinetics. mBio, 2025; 16(1): e01679-24. DOI: https://doi.org/10.1128/mbio.01679-24